智通财经APP讯，威高股份(01066)发布公告，于2025年9月1日斥资221.9万港元回购38万股。 ...

威高股份(01066)发布公告，于2025年9月1日斥资221.9万港元回购38万股。 ...

格隆汇9月1日丨威高股份(01066.HK)公告，9月1日耗资222万港元回购38万股，每股回购价5.8-5.86港 元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01066 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年8月31日 | | 4,511,363,924 | | 10,968,400 | | 4,522,332,324 | | 1). 購回股份 (股份被持作庫存股份) | | | -380,0 ...

致：香港交易及結算所有限公司 公司名稱: 山東威高集團醫用高分子製品股份有限公司 呈交日期: 2025年9月1日 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01066 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 4,522,332,324 | RMB | | 0.1 RMB | | 452,233,232.4 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 4,522,332,324 | RMB | | 0.1 RMB | | 452,233,232.4 | | 2. 股份分 ...

证券时报·数据宝统计显示，8月29日有25家香港上市公司进行了股份回购，合计回购1720.21万股，回购 金额8.69亿港元。 腾讯控股回购数量91.90万股，回购金额5.50亿港元，回购最高价为605.000港元，最低价为594.500港 元，年内累计回购金额455.49亿港元；中国宏桥回购数量892.35万股，回购金额2.27亿港元，回购最高 价为25.440港元，年内累计回购金额39.11亿港元；恒生银行回购数量21.00万股，回购金额2351.69万港 元，回购最高价为112.500港元，最低价为111.500港元，年内累计回购金额4.79亿港元。 以金额进行统计，8月29日回购金额最多的是腾讯控股，回购金额为5.50亿港元；其次是中国宏桥，回 购金额为2.27亿港元；回购金额居前的还有恒生银行、美高梅中国等。回购数量上看，8月29日回购股 数最多的是中国宏桥，当日回购量为892.35万股；其次是威高股份、美高梅中国等，回购数量分别为 126.00万股、100.00万股。 8月29日港股公司回购一览 | 代码 | 简称 | 回购股数 | 回购金额（万 | 回购最高价 | 回购最低价 | 年内累计回购金 ...

| 股票名称 | 回购数 | 回购额 | 年累计回购数量 | 年累计回购数量/总 | | --- | --- | --- | --- | --- | | | | | (股) | 股本 | | 腾讯控股(00700) | 91.90 万 | 5.50 亿 | 4666.10 万 | 0.508% | | 潍柴动力(02338) | 1641.70 万 | 2.50 亿 | 3914.25 万 | 0.449% | | 中国宏桥(01378) | 892.35 万 | 2.27 亿 | 8867.00 万 | 0.950% | | 恒生银行(00011) | 21.00 万 | 2351.69 万 | 423.00 万 | 0.225% | | 美高梅中国(02282) | 100.00 万 | 1606.02 万 | 1062.74 万 | 0.280% | | 中旭未来(09890) | 66.42 万 | 1000.26 万 | 146.92 万 | 2.760% | | 威高股份(01066) | 126.00 万 | 744.79 万 | 432.00 万 | 0.957% | | 贝壳-W(02423 ...

Core Viewpoint - The company's 1H25 performance slightly missed market expectations, but showed a sequential recovery, with revenue of 6.644 billion yuan, a year-on-year increase of 0.1%, and a net profit of 1.008 billion yuan, a year-on-year decrease of 9.0% [1] Performance Summary - 1H25 revenue from the medical device segment was 3.191 billion yuan, showing a year-on-year growth of 0.1%, with volume growth expected to remain in single digits due to pricing pressure from centralized procurement [1] - The pharmaceutical packaging segment generated revenue of 1.166 billion yuan, down 0.1% year-on-year, primarily affected by price reductions from centralized procurement [1] - The interventional segment reported revenue of 1.100 billion yuan, a decline of 1.3% year-on-year, impacted by tariffs and new product promotion costs [1] - The orthopedic segment achieved revenue of 733 million yuan, down 1.6% year-on-year, but saw a significant profit increase of 74% due to stabilization post-centralized procurement [1] Development Trends - The company expects continued acceleration in the second half of 2025, with centralized procurement nearing its end and favorable rules emerging [1] - New product launches in the surgical product category are anticipated to benefit from centralized procurement and import substitution, with a 40% year-on-year increase in 1H25 [1] International Expansion - In 1H25, overseas revenue reached 1.624 billion yuan, a year-on-year increase of 4%, accounting for 24% of total revenue [2] - The company is transitioning from a foreign trade model to localized management and plans to shift production capacity back to China while establishing manufacturing in Southeast Asia [2] Financial Health - As of 1H25, the company had a net cash position of 3.43 billion yuan and operating cash flow of 880 million yuan [2] - The company maintains a 50% dividend payout ratio and invested 316 million yuan in R&D, representing 4.7% of revenue [2] Profit Forecast and Valuation - Due to unexpected price reductions from centralized procurement and foreign exchange losses, the company has lowered its net profit forecasts for 2025 and 2026 by 9.9% and 10.4%, respectively [2] - The current stock price corresponds to a price-to-earnings ratio of 11.6x for 2025 and 10.4x for 2026, with a target price of 6.40 HKD, implying an upside potential of 8.5% [2]

Group 1 - The company, Weigao Group (01066.HK), announced a share buyback on August 29, 2023, spending HKD 7.4479 million to repurchase 1.26 million shares [1] - The buyback price per share ranged from HKD 5.83 to HKD 6 [1]

威高股份(01066)发布公告，于2025年8月29日斥资744.79万港元回购126万股。 ...